Ivermectin is FDA-approved for human use, but only for a narrow set of parasitic conditions, not for COVID-19. The drug has been available in the United States since the late 1980s as a prescription treatment for certain worm infections and parasitic skin conditions. During the pandemic, a collision between a promising laboratory finding and a wave of social media enthusiasm turned ivermectin into one of the most contentious drugs in modern medicine, even as rigorous clinical trials consistently failed to show it helped people with COVID-19.
What Ivermectin Is Actually Approved For
Ivermectin was originally developed as a veterinary antiparasitic in the early 1980s and quickly became one of the most widely used drugs in animal medicine. Shortly after, both the FDA and the World Health Organization approved it for human use against a specific list of parasitic diseases: onchocerciasis (river blindness), strongyloidiasis (a type of intestinal roundworm infection), head lice, scabies, and certain other gastrointestinal worm infestations.1PubMed Central. Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine In the United States, the approved human formulations are limited to oral tablets and a topical cream for rosacea. Veterinary formulations, by contrast, come in a wider array of forms including injectable solutions and oral pastes.
In addition to its licensed uses, ivermectin has a long history of off-label use against parasitic diseases not listed on the label, particularly in veterinary settings and in tropical medicine where other options are scarce.2Antiviral Research. Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug” Its role in global health has been enormous. Discovered in the late 1970s from a soil microorganism isolated in Japan, ivermectin has been donated free of charge for mass drug administration campaigns aimed at eliminating river blindness and lymphatic filariasis worldwide, improving the lives of billions of people in endemic regions.3PubMed Central. Ivermectin, ‘wonder drug’ from Japan: the human use perspective That track record of safety and accessibility is precisely what made the drug an appealing candidate when researchers began hunting for existing medications that might work against SARS-CoV-2.
The Lab Study That Started the COVID Controversy
In June 2020, Australian researchers published a finding that got enormous attention: when they added ivermectin to cells infected with SARS-CoV-2 in a laboratory dish, viral replication dropped roughly 5,000-fold within 48 hours.4Antiviral Research. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro The paper was careful to note that the result warranted further investigation in humans, but the headline-friendly number traveled far faster than the caveats did.
The core problem was one that pharmacologists recognized immediately: the concentration of ivermectin needed to achieve that dramatic effect in a lab dish was far higher than what the drug reaches in human blood at approved doses. Killing a virus in a petri dish is a much lower bar than treating a virus in a living person. Many substances, including household disinfectants, can destroy viruses in vitro without being useful as medicines. The study was scientifically legitimate as a first screening step, but it was never evidence that swallowing ivermectin tablets would clear a COVID infection. That distinction was largely lost in the public conversation.
What Happened When It Was Tested in People
Between 2020 and 2022, multiple large randomized clinical trials tested whether ivermectin given to COVID patients actually reduced hospitalizations, sped recovery, or prevented death. The results were consistent and disappointing for ivermectin advocates.
A large trial published in the New England Journal of Medicine enrolled nearly 1,400 outpatients with early COVID-19. About 15% in the ivermectin group had a progression event (hospitalization or prolonged emergency observation), compared with about 16% in the placebo group. The difference was not meaningful, and the researchers concluded that ivermectin did not lower the incidence of hospital admission.5PubMed. Effect of Early Treatment with Ivermectin among Patients with Covid-19 A separate trial focusing on higher-risk patients with existing health conditions found an even more discouraging pattern: about 22% of the ivermectin group progressed to severe disease versus about 17% in the control group, a non-significant trend in the wrong direction.6PubMed Central. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities A third major trial tested higher doses given over six days and likewise found no benefit for time to sustained recovery.7JAMA. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19
When researchers pooled the evidence, the picture did not change. A Cochrane systematic review, widely considered the gold standard for evidence synthesis, examined 11 trials with over 3,400 participants and concluded that for outpatients there was low- to high-certainty evidence that ivermectin provided no beneficial effect.8Cochrane Database of Systematic Reviews. Ivermectin for preventing and treating COVID-19 A separate meta-analysis of 19 randomized trials reached the same conclusion: ivermectin was not associated with reduced mortality, shorter hospitalization, less clinical worsening, or faster viral clearance compared to placebo or standard care.9PubMed Central. Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs
Why Some Early Studies Looked Promising
If the final verdict is this clear, why did enthusiasm build so strongly? Part of the answer lies in the quality of some early trials. Several small studies from 2020 and early 2021 reported large benefits, and a few were widely shared as proof ivermectin worked. But as scrutiny increased, serious problems emerged. One of the most influential early meta-analyses relied heavily on a large study that was later withdrawn because of fraudulent data. The journal that published the meta-analysis issued an expression of concern and the authors revised their analysis after the fraud was exposed.10Open Forum Infectious Diseases. Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection When the tainted studies were removed, the apparent benefits largely vanished. This pattern, where a handful of flawed or fabricated studies inflate a treatment’s apparent efficacy, is not unique to ivermectin, but it played a central role in shaping public perception before the larger, better-designed trials reported their results.
Safety at Standard Doses Versus Pandemic Misuse
At the doses approved for parasitic infections, ivermectin has a well-established safety profile built on decades of mass distribution. Research has shown it has a wide therapeutic index, with doses up to ten times the FDA-approved level being tolerated in controlled studies.11PubMed Central. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL) At standard doses, side effects tend to be mild: headache, dizziness, nausea, or skin rash. For the parasitic conditions it is designed to treat, the benefit-risk balance is favorable and well understood.
The pandemic changed that calculation. As demand surged among people seeking ivermectin for COVID, many turned to veterinary formulations or unregulated sources when they could not get a prescription. Poison control data from California showed that ivermectin-related exposure reports had been steady at around 14 to 15 per month before late 2020 and then climbed by about two additional cases per month through the end of 2021.12PubMed Central. Exposures to Bleach, Peroxide, Disinfectants, Antimalarials, and Ivermectin Reported to the California Poison Control System Before and During the COVID-19 Pandemic, 2015-2021 An analysis of toxicity cases found that the most common symptoms were neurological effects, gastrointestinal distress, and musculoskeletal complaints. People who used veterinary products tended to take higher doses and had higher rates of altered mental status than those using prescription tablets. People who took ivermectin chronically at lower doses over weeks also developed toxicity, though typically milder.13PubMed. Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19
Counterfeit and Substandard Products
Beyond the risk of overdosing on legitimate veterinary formulations, the pandemic demand also spawned a market in counterfeit ivermectin products. Belgian regulatory agencies intercepted large quantities of ivermectin tablets between 2021 and 2022 and sent them for laboratory analysis. Not a single one of the 19 tested samples met the quality standards required of a legitimate medicine. Some were systematically under-dosed, meaning the pills contained far less ivermectin than claimed. Others were severely contaminated with bacteria, including pathogens known to cause gastrointestinal illness.14PubMed Central. Substandard and falsified ivermectin tablets obtained for self-medication during the COVID-19 pandemic as a source of potential harm Buying ivermectin through unregulated channels carried not just the risk of taking too much of the drug but of swallowing something contaminated or largely inert.
Drug Interactions Worth Knowing About
Ivermectin is processed in the liver primarily by a single enzyme called CYP3A4. That means any drug that strongly blocks or revs up this enzyme can change how quickly your body clears ivermectin, potentially leading to drug levels that are too high or too low.15PubMed Central. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects Common CYP3A4 inhibitors include certain antifungal medications, some antibiotics, and grapefruit juice. When prescribed for parasitic infections, the drug is typically given as a single dose or a short course, which limits the window for interactions. But during the pandemic, some people took ivermectin daily for weeks, dramatically increasing the chance that a co-administered medication could push drug levels into a problematic range.
In tropical medicine settings, where ivermectin may be co-administered with antimalarial drugs, lab studies have identified several antimalarials that substantially inhibit ivermectin metabolism. Piperaquine and mefloquine showed the strongest interactions, while chloroquine and proguanil also had meaningful effects.16PubMed Central. Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds These interactions matter primarily in regions where co-infection with parasites and malaria is common, but they illustrate a general principle: ivermectin’s metabolism is easily altered by other medications, and its safety profile under such conditions is less well characterized than its safety as a standalone single dose.
Why Some Animals and People Are Especially Vulnerable
Ivermectin’s safety depends heavily on a protein called P-glycoprotein, which acts as a gatekeeper at the blood-brain barrier, pumping the drug back out of the central nervous system before it can accumulate. When this transporter does not work properly, ivermectin can build up in the brain and cause severe neurotoxicity.
The best-known example comes from dogs. In 2001, researchers identified that “ivermectin sensitivity” in herding breeds like Collies and Australian Shepherds is caused by a genetic variant of the MDR1 gene, which codes for P-glycoprotein.17PubMed Central. Canine and feline P-glycoprotein deficiency: What we know and where we need to go Dogs with this mutation can develop coma and die from doses that would be safe in other breeds. A broader review of ivermectin toxicity across species confirms that impairment or saturation of P-glycoprotein-mediated efflux is the central driver of neurotoxicity, with neonatal animals, genetically predisposed breeds, and subjects exposed to transporter-inhibiting drugs all showing pronounced vulnerability.18PubMed Central. Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management
In humans, the situation is more nuanced. A clear loss-of-function mutation in the equivalent gene has not been identified as a common problem, but research on patients in Cameroon who experienced serious adverse events after ivermectin treatment found that certain gene variants associated with altered drug handling were present as matched pairs in half of the affected patients and absent in controls.19PubMed Central. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event In those cases, a combination of high parasite loads (specifically co-infection with a different parasitic worm called Loa loa) and a genetic predisposition to altered ivermectin distribution appeared to set the stage for serious reactions. This is an edge case relevant mainly in Central African countries where Loa loa is endemic, but it underscores that individual variation in drug handling exists in humans, not just in Collies.
The Role of Misinformation in Driving Demand
The gap between what the evidence showed and what millions of people believed about ivermectin during the pandemic was strikingly large, and researchers have tried to understand why. A survey-based study published in JAMA Health Forum found that people who endorsed at least one piece of COVID-19 vaccine misinformation were roughly three times as likely to have taken non-evidence-based medications like ivermectin. Trust patterns mattered too: people who reported trusting scientists were less likely to have used such medications, while those who reported trusting social media were about two and a half times more likely to have done so.20PubMed Central. Misinformation, Trust, and Use of Ivermectin and Hydroxychloroquine for COVID-19 Greater endorsement of conspiracy thinking was also independently associated with use of these treatments.
None of this means every person who took ivermectin for COVID was a conspiracy theorist. Desperate patients in a frightening pandemic naturally looked for anything that might help, and early signals from small studies and in vitro work gave the idea a patina of scientific plausibility. But the speed at which a lab curiosity became a populist cause, outpacing the clinical evidence by years, is a case study in how health misinformation can drive real-world harm, from poison control calls to patients delaying effective treatment.
Anthelmintic Resistance and the Future of Ivermectin
Separate from the COVID controversy, ivermectin faces a slow-moving challenge in its core role as an antiparasitic. In livestock medicine, resistance to ivermectin is already a serious and growing problem, and there are concerns about resistance developing and spreading in parasites that infect humans.21PubMed. Ivermectin resistance and overview of the Consortium for Anthelmintic Resistance SNPs Genome-wide studies of ivermectin-resistant worm populations in sheep have identified a major genetic region associated with resistance, but the mechanism does not map neatly to previously suspected candidate genes, suggesting something new and not yet fully understood is at work.22bioRxiv. Population genomic and evolutionary modelling analyses reveal a single major QTL for ivermectin drug resistance in the pathogenic nematode, Haemonchus contortus
Mass drug administration programs that distribute ivermectin to millions of people annually for river blindness and lymphatic filariasis create selection pressure on the targeted parasites. Ivermectin is also being explored for use against malaria-carrying mosquitoes, which would introduce yet another widespread exposure. A scoping review of resistance mechanisms in ectoparasites warns that although reports of resistance in human parasites remain few, the development of resistance in mosquito populations should be anticipated and monitored.23PubMed Central. Ivermectin resistance mechanisms in ectoparasites: a scoping review The irony is notable: pandemic-era self-medication with ivermectin for a condition it does not treat may, in some small way, accelerate resistance pressure on a drug that remains genuinely irreplaceable for the parasitic diseases it was designed to fight.